These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17440804)

  • 1. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
    Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
    J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
    Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
    PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity.
    Huet T; Kerbarh O; Schols D; Clayette P; Gauchet C; Dubreucq G; Vincent L; Bompais H; Mazinghien R; Querolle O; Salvador A; Lemoine J; Lucidi B; Balzarini J; Petitou M
    Antimicrob Agents Chemother; 2010 Jan; 54(1):134-42. PubMed ID: 19805567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.
    Shimura K; Nameki D; Kajiwara K; Watanabe K; Sakagami Y; Oishi S; Fujii N; Matsuoka M; Sarafianos SG; Kodama EN
    J Biol Chem; 2010 Dec; 285(50):39471-80. PubMed ID: 20937812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of Fusion Inhibitor Resistance Mutations Among Therapy-Naïve HIV Patients.
    Ghassabi F; Hashempour A; Dehghani B; Hasanshahi Z; Khodadad N; Behizadeh F; Davarpanah MA
    AIDS Res Hum Retroviruses; 2024 Apr; ():. PubMed ID: 38553905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phage therapy: a revolutionary shift in the management of bacterial infections, pioneering new horizons in clinical practice, and reimagining the arsenal against microbial pathogens.
    Karn SL; Gangwar M; Kumar R; Bhartiya SK; Nath G
    Front Med (Lausanne); 2023; 10():1209782. PubMed ID: 37928478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
    Jang DH; Yoon CH; Choi BS; Chung YS; Kim HY; Chi SG; Kim SS
    J Korean Med Sci; 2014 Mar; 29(3):456-9. PubMed ID: 24616600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short communication: Simultaneous substitutions of V38M and N43T-N44K in the gp41 heptad repeat 1 (HR1) disrupt HIV type 1 gPr160 endoproteolytic cleavage (*).
    Morozov VA; Morozov AV; Lagaye S
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):73-7. PubMed ID: 20055586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.
    Stürmer M; Doerr HW; Gürtler L
    Med Microbiol Immunol; 2009 Aug; 198(3):147-55. PubMed ID: 19495792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
    Jenwitheesuk E; Samudrala R
    Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
    Matthews T; Salgo M; Greenberg M; Chung J; DeMasi R; Bolognesi D
    Nat Rev Drug Discov; 2004 Mar; 3(3):215-25. PubMed ID: 15031735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
    Morozov VA; Morozov AV; Schürmann D; Jessen H; Kücherer C
    Virus Genes; 2007 Oct; 35(2):167-74. PubMed ID: 17440804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
    Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
    AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
    Becker Y
    Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.